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Background: Steroid cell tumors of ovary account for less than 0.1% of all ovarian tumors and these tumours may
present at any age in association with interesting presentations related to hormonal activities. The subtype, not
otherwise specified (NOS), is associated with androgenic changes in 56-77% and Cushing syndrome in 6-10%. Due
to the rarity of available data regarding these tumors, little is known about their malignant potential and metastatic
behaviour. We hereby report an unusual metastasis of steroid cell ovarian neoplasm presented with both Cushing
syndrome and hyperandrogenemia.
Case presentation: A 31-year-old woman, who had a past medical history of ovarian tumor resection (left ovarian
thecoma was initially diagnosed at that time), presented with hirsutism, hypertension and menstrual disorder. Also,
laboratory work-up revealed hypercortisolism and androgen excess. Computerized tomography (CT) of the
abdomen showed abdominal paraaortic masses, multiple intrahepatic nodules and retroperitoneal lymph nodes
enlargement. Positron emission tomography/computed tomography (PET/CT) scan demonstrated metastatic lesions.
Her ovarian tumor sections were re-examined and pathology result was corrected to steroid cell tumor (NOS) associated
with active cell growth and necrosis. Subsequent excision of metastatic lesions yielded clinical improvement promptly
and metastasis of steroid cell tumor was confirmed by postoperative pathological studies. However, one year after the
surgical management of metastasis, recurrence happened while radiotherapy was ineffective. The patient finally died of
tumor metastatic recurrence.
Conclusion: This case reports a rare coexistence of Cushing syndrome and hyperandrogenemia which occurs based
on metastasis of steroid cell ovarian neoplasm. It presents a real diagnostic challenge to both clinicians and
pathologists. Therefore, it is very important to establish a final diagnosis by pathological studies along with clinical
manifestations and imaging findings. Besides, it is necessary to improve follow-up of patients with this kind of tumors.
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HyperandrogenemiaBackground
Steroid cell tumors (SCTs) of the ovary are a rare sub-
group of sex cord-stromal tumors (SCSTs), representing
less than 0.1% of all ovarian tumors [1] and usually occur-
ring in adults with an average age at diagnosis of 47 years
old [2]. These tumors can produce steroids and may give
interesting presentations related to hormonal activities
[3-10]. There are three subtypes of such tumors based on* Correspondence: tjmughen@163.com
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Leydig cell tumor arising from Leydig cells in the hilus,
and steroid cell tumor (not otherwise specified, or NOS)
when the lineage of the tumor is unknown [1]. The last
subtype is usually associated with androgenic changes in
56-77%, estrogen secretion in 6-23%, and Cushing syn-
drome in 6-10%.
Due to the rarity of available data regarding SCTs, little
is known regarding their malignant potential and meta-
static behaviour. So far, very few cases have been reported
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location
Figure 1 Pelvic CT scan showing no recurrent or residual mass
in the left adnexa location, and the right ovary and the uterus
were of normal appearance.
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of ovarian steroid cell tumor (NOS) which secreted both
cortisol and androgen and caused Cushing syndrome and
hyperandrogenemia 3 years after the initial tumor was
removed.Case presentation
A 31 year-old-woman who had a past history of left oo-
phorectomy was admitted to our hospital with marked
hirsutism and menstrual disorder as well as significant
hypertension.
Three years and six months before the admission, the
patient had irregular menses and excess hair growth on
her face, neck, chest, abdomen and thighs. Her face be-
came round. Her skin became thin and bruised easily.
Then she turned to a local clinic where physical examination
showed that she had a blood pressure of 160/120 mmHg.
Meanwhile, gynecologic ultrasonography demonstrated a
25 × 20 × 15 cm left ovarian mass. Routine laboratory
workup revealed the following: leukocytosis (11.2 × 109/L)
with neutrophilia (76.6%), hypokalemia (3.3 mmol/L) andFigure 2 Abdominal CT scan showing two masses (white arrows) bes
(black arrows) and retroperitoneal lymph nodes enlargement.elevated fasting glucose (6.4 mmol/L). Hormonal assays
were not conducted. She received left oophorectomy and
pathology result was luteinized thecoma of the ovary with
focal coagulative necrosis and calcification. Since the pa-
tient desired future fertility strongly, she refused total ab-
dominal hysterectomy with contralateral oophorectomy.
Postoperatively, the patient’s symptoms of hirsutism and
round face were resolved. Her menstrual period and blood
pressure returned to normal. Two year later, she gave a
natural childbirth and had no difficulty in breast-feeding.
Four months prior to admission, the patient had hirsut-
ism and menstrual disorder again. Simultaneously, she
noted a left abdominal mass. From then on, she found her
face became round gradually. Her blood pressure went up
to 180/110 mmHg, resulting in blurred vision. Her body
weight dropped by 3 Kg druing four months while her
height did not change. A mass (11 × 8.1 × 5.6 cm) beside
abdominal aorta was detected by ultrasound. Lab tests
showed her tumor markers (serum Ca-125, Ca19-9,
Ca153, CEA and AFP) and 24-hrs urinary VMA were
within normal limits. Antihypertensive drug Doxazosin
4 mg/d was given, but her hypertension was not well con-
trolled. For further diagnosis and treatment, the patient
was admitted to our hospital.
During physical examination her blood pressure was
195/130 mmHg. She was 147 cm tall and weighed 54 kg
(body mass index 25.0). She had hirsutism and her skin
was thin with scattered ecchymosis. She had a round
and plethoric face, central adiposity, buffalo hump and
supraclavicular fat pads. A mass of 7 × 5 cm could be
palpated in the left mid-abdomen. There were no purple
striae and hyperpigmentation.
Her baseline labs showed normal WBC count (6.66 ×
109/L) with neutrophilia (74.7%), hypokalemia (3.11 mmol/L),
impaired glucose tolerance (fasting glucose 6.7 mmol/L, 2-hrs
postprandial glucose 10.6 mmol/L) and alkalosis (pH 7.54,
base excess 9.0 mmol/L). Urine potassium level was
within the normal range (50 mmol/24 hr, reference range
25–100) but was relatively high given her hypokalemia.
An endocrinological evaluation revealed elevated morning
plasma cortisol (31 μg/dl, ref. range 5–25), and overnightide abdominal aorta, multiple intrahepatic hypodense nodules
Figure 3 Enhanced abdominal CT scan showing two masses (white arrows), multiple intrahepatic nodules (black arrows) and
retroperitoneal enlarged lymph nodes, all enhanced with contrast media.
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of cortisol. Urinary free cortisol was extremely high
(1024.8 μg/24 hr, ref. range 30–110) and plasma ACTH
was relatively low (16 pg/ml, ref. range 0–46). In addition,
her testosterone level rose to 98 ng/dL (ref. range 14–76)
with normal LH, FSH, prolactin and estradiol. Pelvic CT
scan showed no recurrent or residual mass in the left ad-
nexa location and the right ovary and the uterus were of
normal appearance (Figure 1). However, abdominal CT
scan demonstrated two masses beside abdominal aorta,
multiple intra-hepatic hypodense nodules, and retroperi-
toneal lymph nodes enlargement (Figure 2), all enhanced
with contrast media (Figure 3). These were compatible
with metastatic disease. At the same time, mild adrenal at-
rophy without ascites was detected in her CT scan. Her
previous ovarian tumor sections were re-examined and
the pathology result was corrected to steroid cell tumor,
NOS (cpinephroma) associated with active cell growth
and necrosis (Figure 4). The patient was strongly inter-
ested in tumor-reductive surgery. During a pre-surgical
work-up, the patient had positron emission tomography/
computed tomography (PET/CT) which revealed abnor-
mally hypermetabolism in the retroperitoneal masses andFigure 4 Histologic section obtained from the ovarian tumor.
Stain: hematoxylin and eosin.nodes suggesting metastatic lesions (Figure 5). Therefore,
she underwent excisions of abdominal paraaortic neo-
plasms and multiple intra-hepatic nodules as well as retro-
peritoneal enlarged lymph nodes. The cut surface of the
neoplasms showed a solid mass including hemorrhagic
and necrotic contents with calcific deposits. The resected
specimens showed very similar appearances of histo-
pathology to the previous ovarian tumor. Neoplastic
cells were calretinin, CD99, α-inhibin positive, cytokera-
tin (CK), vimentin weak positive and epithelial mem-
brane antigen (EMA) negative by immunohistochemical
staining. These findings were consistent with the diag-
nosis of malignant steroid cell tumor (NOS) with late
intra-abdominal metastasis.
By the 4th postoperative day, her morning plasma cortisol
fell to 6 μg/dl while plasma ACTH was up to 41.7 pg/ml.
Meanwhile, her plasma testosterone fell to 50 ng/dl and
urinary free cortisol fell to less than 36 μg/24 hr (Table 1).
During postoperative follow-up (four months after sur-
gery), she showed regression of Cushing syndrome and
regained normal menses and blood pressure. Furthermore,
her hirsutism disappeared completely. Nevertheless, one
year after surgery, metastatic tumors appeared again in
the abdominal cavity. Although the patient was given
radiotherapy at once, she died of tumor metastatic recur-
rence sixteen months after surgery.
Discussion
We herein present a case of a woman who initially had
hirsutism, menstrual disorder and hypertension due to
ovarian tumor and developed cortisol and androgen co-
secreting intra-abdominal metastasis without evidence of
recurrence of the primary ovarian lesion three years after
the initial tumor was removed. The tumor was originally
diagnosed as luteinized thecoma of the ovary, but at
retrospective review the tumor turned out to have subtle
features of steroid cell tumor (NOS) such as hypercorti-
solism and androgen excess.
The most common cause of Cushing syndrome is pi-
tuitary or adrenal adenoma. However, in the case of
intra-abdominal masses, different etiologies are possible.
Figure 5 PET/CT revealed abnormally hypermetabolism in the retroperitoneal masses (white arrows) and nodes suggesting
metastatic lesions.
Yuan et al. BMC Endocrine Disorders 2014, 14:12 Page 4 of 6
http://www.biomedcentral.com/1472-6823/14/12On the one hand, the patient had some typical clinical
features of Cushing syndrome except that she was over-
weight but thin, which might be caused by underlying
devastating malignancy. Her lab tests revealed elevated
plasma cortisol which overnight dexamethasone (1 mg)
failed to suppress. Thus, Cushing syndrome could be di-
agnosed. On the other hand, her plasma ACTH was
relatively low and the CT images indicated mild adrenal
atrophy and intra-abdominal metastatic tumors. As a re-
sult, pituitary or adrenal adenoma as well as ectopic
ACTH secretion could be ruled out. Based on the above
facts and her history of ovarian tumor, paraneoplastic ec-
topic cortisol secretion was deemed as most likely despite
of its rarity. But it was puzzling that ovarian thecoma
could not secrete cortisol. Fortunately, her previous ovar-
ian tumor sections were found and the pathological diag-
nosis of luteinized thecoma was overthrown and corrected
to steroid cell tumor (NOS). Ultimately, the patient was
diagnosed as malignant steroid cell tumor (NOS) with late
intra-abdominal metastasis on the basis of postoperative
pathology result. The diagnosis was proved correct by the
fact that her symptoms of Cushing syndrome disappeared
and her plasma and urinary levels of cortisol decreased
significantly after the metastatic lesions were removed.
Also in this case no hormone evaluation was performed at
the first surgery, but clinical signs strongly suggested co-
secretion of cortisol and androgen. Discrepancy between
clinics and biology first, and the first result of pathology
led to a second pathology reading. Attention should be
paid to such a discrepancy by clinicians, in a way that a






Plasma cortisol 31 μg/dl 6 μg/dl 5–25 μg/dl
Plasma ACTH 16 pg/ml 41.7 pg/ml 0–46 pg/ml
Plasma
testosterone
98 ng/dl 50 ng/dl 14–76 ng/dl
Urinary free
cortisol
1024.8 μg/24 hr <36 μg/24 hr 30–110 μg/24 hrafter the first surgery, which should have led to an appro-
priate and strict follow-up.
In addition, the patient also presented with hirsutism,
which might result from hyperandrogenemia rather than
hypercortisolemia. Routine screening for Cushing syn-
drome in women presented with hirsutism is a contro-
versial issue. In a recent study, Karaca et al. screened
105 patients with the main complaint of hirsutism for
Cushing syndrome irrespective of their suggestive findings
of hypercortisolemia. None of the patients was diagnosed
as Cushing syndrome by low-dose dexamethasone sup-
pression test. Therefore, they concluded that routine
screening for Cushing syndrome in hirsute patients is not
required if the patient does not have accompanying clin-
ical stigmata of hypercortisolism [11].
Sex cord-stromal tumors are developed from the sex
cord and stromal components of the gonad. Ovarian
SCTs are grouped under SCSTs, and they are usually be-
nign, unilateral, and formed by steroid cell proliferation.
Between the three subtypes of SCTs, nearly 60% are ster-
oid cell, NOS tumors. Microscopically, steroid cell tu-
mors (NOS) are generally composed of large, round to
polyhedral cells with vacuolated cytoplasm as well as
smaller cells with eosinophilic granular cytoplasm, which
are usually diffusely arranged in nests, clusters, cords or
columns resembling adrenal zona glomerulosa and zona
fasciculate. In this case, steroid cell tumor (NOS) was
misinterpreted as luteinized thecoma, a typical thecoma
throughout which clusters of large eosinophilic, lipid-
laden lutein cells are scattered. Luteinized thecoma con-
tains plump spindle cells and therefore is distinguishable
from steroid cell tumor (NOS). In addition to these micro-
scopic findings, steroid cell tumors would require immu-
nohistochemical markers for accurate diagnosis. Inhibin
and calretinin are the most useful markers for the discrim-
ination of sex cord stromal tumors from other tumors
[12]. Most of the steroid cell tumors are positive for calre-
tinin and inhibin [13]. In an immunohistochemical study
on 215 ovarian tumors, caleritinin was found to be a sen-
sitive marker for sex cord tumors; however, it was a less
specific marker than inhibin in differentiating these
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cord stromal tumors are mostly negative to EMA [12,15].
Histopathologic evaluation for the patient showed
inhibin- and calretinin-positive and EMA-negative im-
munohistochemical findings which made the diagnosis
easier. However, some authors have also reported calretinin-
negative steroid cell tumors [16,17].
Although most steroid cell tumors (NOS) behave in a
benign fashion, malignancy has been reported in as high
as 43% of cases [18]. Absolute indication of malignancy
is extraovarian metastasis. Furthermore, malignancy is
generally associated with identification of the histopath-
ologic findings: two or more mitotic figures per 10 high-
power fields, grade 2/3 nuclear atypia, vascular invasion,
and a diameter of greater than 7 cm with necrosis or
hemorrhage on the gross specimen [1]. The size of the
ovarian tumor, presence of necrosis, and nuclear pleo-
morphism in the present case were suggestive of a ma-
lignant nature. Three years later, extraovarian metastasis
was confirmed malignancy.
Surgical intervention is the most important and hall-
mark treatment, and complete excision of the tumor
could contribute to the regression of symptoms and
disappearance of Cushing syndrome. However, young
woman are usually conservative towards this solution
due to concern of losing fertility. If future fertility is not
an issue, hysterectomy, removal of the contralateral
ovary, and complete surgical staging are recommended.
Age, large tumor size, lymph node involvement, and re-
sidual disease are all predictors of poor prognosis [19].
For stage 2–4 disease, adjuvant radiotherapy or chemo-
therapy can be implemented, but there are no reports of
effective radiation or chemotherapy. An optimal adju-
vant chemotherapeutic regiment has not yet been devel-
oped, with treatments by the BEP regimen and the
carboplatin and paclitaxel regimen yielding equivocal re-
sults [20]. Further observation into the nature, biology
and behaviour of the tumor may improve the under-
standing of therapeutic value of radiation or chemother-
apy over time.
Conclusion
This case reports a rare coexistence of Cushing syn-
drome and hyperandrogenemia which can occur based
on ovarian pathology in females. Metastasis of steroid
cell ovarian neoplasm resulting in co-secretion of corti-
sol and androgen is extremely rare and represents a real
diagnostic challenge for both clinicians and pathologists.
A correct diagnosis usually involves a multidisciplinary
effort and neglect of clinical features only results in mis-
diagnosis. Therefore, it is very important to establish a
final diagnosis by pathological studies along with clinical
manifestations and imaging findings. Besides, this pa-
tient developed steroid-secreting metastasis three yearsafter the excision of primary tumor, and then one year
after surgical management of metastasis, recurrence
happened while radiotherapy was ineffective. These fea-
tures of this case illustrate the necessity for this kind of
tumor follow-up.
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